MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective

    E. Pipan, S. Delalić, A. Herzog, M. Trošt, Z. Pirtošek, D. Flisar, N. Kovacs, D. Georgiev (Ljubljana, Slovenia)

  • Impulse Control Disorders in a Brazilian population with Parkinson´s disease -an observational study

    B. Veiga, V. Borges, H. Ferraz, C. Aquino, C. Giacominelli, SM. Silva, S. Lestingi (São Paulo, Brazil)

  • In the shadow of Parkinson disease: what to tell patients with REM sleep behavior disorder?

    D. Barone, A. Lee, N. Hellmers, S. Lakhani, H. Sarva, C. Henchcliffe (New York, NY, USA)

  • In vivo and In vitro study of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats : A therapeutic potential drug for Alzheimer’s disease

    P. Kumar, N. Baquer (New Delhi, India)

  • In vivo increased striatal iron deposition in Parkinson’s Disease Dementia and Dementia with Lewy Body

    S. Rota, T. Yousaf, H. Wilson, G. Dervenoulas, G. Pagano, D. Aarsland, M. Politis (London, United Kingdom)

  • Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

    B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.

    F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data

    R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data

    F. Ikedo, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

    R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • « Previous Page
  • 1
  • …
  • 103
  • 104
  • 105
  • 106
  • 107
  • …
  • 217
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley